Schultes Birgit C
SEC insider (Form 3/4/5 filer). CIK 0002051419. EVP, Chief Scientific Officer at Intellia Therapeutics, Inc. (NTLA). 4 reported Form 4/5 transactions since Sep 2024; latest on Mar 1, 2026. Located in CAMBRIDGE, MA.
Companies Schultes Birgit C has filed insider reports for
- Intellia Therapeutics, Inc. (NTLA): Officer, EVP, Chief Scientific Officer
Schultes Birgit C
CIK: 0002051419
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (50.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NTLA
Intellia Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Mar 1, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect39.2K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect8.5K shares at avg. $9.21$78K - Oct 1, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect31 shares at avg. $17.38$538.78 - Mar 1, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect37.6K shares-
1-4 of 4 transactions